HN2001000012A - Tratamiento de la enfermedad neurodegenerativa - Google Patents
Tratamiento de la enfermedad neurodegenerativaInfo
- Publication number
- HN2001000012A HN2001000012A HN2001000012A HN2001000012A HN2001000012A HN 2001000012 A HN2001000012 A HN 2001000012A HN 2001000012 A HN2001000012 A HN 2001000012A HN 2001000012 A HN2001000012 A HN 2001000012A HN 2001000012 A HN2001000012 A HN 2001000012A
- Authority
- HN
- Honduras
- Prior art keywords
- treatment
- neurodegenerative disease
- cycline
- mammals
- kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRESENTE INVENCION SE RELACIONA CON UN METODO DE TRATAMIENTO DE LAS ENFERMEDADES NEURODEGENERATIVAS EN MAMIFEROS MEDIANTE LA ADMINISTRACION DE COMPUESTOS QUE INHBEN LAS ENCIMAS QUINASAS DEPENDIENTE DE LA CICLINA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17840000P | 2000-01-27 | 2000-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
HN2001000012A true HN2001000012A (es) | 2001-07-09 |
Family
ID=22652409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HN2001000012A HN2001000012A (es) | 2000-01-27 | 2001-01-24 | Tratamiento de la enfermedad neurodegenerativa |
Country Status (22)
Country | Link |
---|---|
US (1) | US20040224958A1 (es) |
EP (1) | EP1255755A1 (es) |
JP (1) | JP2003523358A (es) |
KR (1) | KR20020070520A (es) |
CN (1) | CN1433417A (es) |
AR (1) | AR029437A1 (es) |
AU (1) | AU1808601A (es) |
BR (1) | BR0017075A (es) |
CA (1) | CA2394525A1 (es) |
CO (1) | CO5280216A1 (es) |
CZ (1) | CZ20022521A3 (es) |
GT (1) | GT200100005A (es) |
HN (1) | HN2001000012A (es) |
HU (1) | HUP0203803A3 (es) |
IL (1) | IL150742A0 (es) |
PA (1) | PA8510801A1 (es) |
PE (1) | PE20011228A1 (es) |
PL (1) | PL357634A1 (es) |
SK (1) | SK10772002A3 (es) |
SV (1) | SV2002000287A (es) |
TN (1) | TNSN01018A1 (es) |
WO (1) | WO2001055148A1 (es) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7053070B2 (en) * | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
US7235551B2 (en) * | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
JP4524072B2 (ja) | 2000-10-23 | 2010-08-11 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規化合物 |
MXPA03007623A (es) * | 2001-02-26 | 2003-12-04 | Tanabe Seiyaku Co | Derivado de piridopirimidina o naftiridina. |
EP1767525A1 (en) | 2001-04-09 | 2007-03-28 | Novartis Vaccines and Diagnostics, Inc. | Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists |
US7105667B2 (en) | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
WO2002102313A2 (en) | 2001-06-19 | 2002-12-27 | Bristol-Myers Squibb Company | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
WO2003032997A1 (de) | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
DK1470124T3 (da) * | 2002-01-22 | 2006-04-18 | Warner Lambert Co | 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner |
DE60315826T2 (de) * | 2002-04-19 | 2008-05-21 | Smithkline Beecham Corp. | Neue verbindungen |
US7384937B2 (en) | 2002-11-06 | 2008-06-10 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
JP2006508997A (ja) * | 2002-11-28 | 2006-03-16 | シエーリング アクチエンゲゼルシャフト | Chk−、Pdk−およびAkt−阻害性ピリミジン、それらの製造および薬剤としての使用 |
US7157455B2 (en) * | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
KR100767272B1 (ko) | 2003-05-05 | 2007-10-17 | 에프. 호프만-라 로슈 아게 | Crf 활성을 갖는 융합 피리미딘 유도체 |
PL1685131T3 (pl) | 2003-11-13 | 2007-08-31 | Hoffmann La Roche | Hydroksyalkilo-podstawione pirydo-7-pirymidyn-7-ony |
BRPI0507668A (pt) * | 2004-02-14 | 2007-07-17 | Irm Llc | compostos e composições como inibidores de proteìna cinase |
JP2007523151A (ja) * | 2004-02-18 | 2007-08-16 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 2−(ピリジン−3−イルアミノ)−ピリド[2,3−d]ピリミジン−7−オン |
JP2008510770A (ja) * | 2004-08-26 | 2008-04-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Plk阻害剤としての新規プテリジノン |
JP5111113B2 (ja) * | 2004-12-13 | 2012-12-26 | サネシス ファーマシューティカルズ, インコーポレイテッド | Rafキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン |
US20090137550A1 (en) * | 2005-03-25 | 2009-05-28 | Glaxo Group Limited | Novel Compounds |
PE20061351A1 (es) | 2005-03-25 | 2007-01-14 | Glaxo Group Ltd | COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38 |
KR20080002865A (ko) * | 2005-03-25 | 2008-01-04 | 글락소 그룹 리미티드 | 피리도[2,3-d]피리미딘-7-온 및3,4-디히드로피리미도[4,5-d]피리미딘-2(1h)-온유도체의 제조 방법 |
TW200724142A (en) * | 2005-03-25 | 2007-07-01 | Glaxo Group Ltd | Novel compounds |
US8247408B2 (en) | 2005-10-07 | 2012-08-21 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer |
CN101395155A (zh) | 2005-10-07 | 2009-03-25 | 埃克塞里艾克西斯公司 | PI3Kα的吡啶并嘧啶酮抑制剂 |
MEP8009A (en) | 2006-09-15 | 2011-12-20 | Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors | |
JP5302389B2 (ja) * | 2008-04-29 | 2013-10-02 | エフ.ホフマン−ラ ロシュ アーゲー | Jnkのピリミジニルピリドンインヒビター |
EP2350070A1 (en) | 2008-09-30 | 2011-08-03 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of pi3k and mtor |
EP2344502A2 (en) | 2008-10-22 | 2011-07-20 | F. Hoffmann-La Roche AG | Pyrimidinyl pyridone inhibitors of jnk |
US20130059824A1 (en) * | 2009-11-23 | 2013-03-07 | Afraxis, Inc. | Methods for treating mild cognitive impairment |
US8889696B2 (en) | 2009-12-18 | 2014-11-18 | Temple University—Of the Commonwealth System of Higher Education | Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof |
US8901137B2 (en) | 2010-02-09 | 2014-12-02 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors |
WO2011156640A2 (en) * | 2010-06-09 | 2011-12-15 | Afraxis, Inc. | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS |
US8912203B2 (en) | 2010-06-09 | 2014-12-16 | Afraxis Holdings, Inc. | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders |
WO2011156786A2 (en) * | 2010-06-10 | 2011-12-15 | Afraxis, Inc. | 6-(ethynyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
US20130252967A1 (en) * | 2010-06-10 | 2013-09-26 | Afraxis, Inc. | 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
US20130338153A1 (en) * | 2010-06-10 | 2013-12-19 | Afraxis, Inc. | 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
JP5512894B2 (ja) * | 2010-08-05 | 2014-06-04 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 2−置換−8−アルキル−7−オキソ−7,8−ジヒドロピリド[2,3d]ピリミジン−6−カルボニトリル及びその使用 |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
AU2013235344B2 (en) * | 2012-03-22 | 2017-03-16 | Oscotec Inc. | Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors |
US9670213B2 (en) * | 2012-05-14 | 2017-06-06 | East China University Of Science And Technology | Pteridine ketone derivative and applications thereof as EGFR, BLK, and FLT3 inhibitor |
PT3495367T (pt) | 2012-06-13 | 2020-11-12 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
EP2968331B1 (en) | 2013-03-14 | 2020-07-01 | Icahn School of Medicine at Mount Sinai | Pyrimidine compounds as kinase inhibitors |
TWI715901B (zh) | 2013-04-19 | 2021-01-11 | 美商英塞特控股公司 | 作為fgfr抑制劑之雙環雜環 |
KR20160035411A (ko) * | 2014-09-23 | 2016-03-31 | 주식회사 오스코텍 | LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
CN113004278B (zh) | 2015-02-20 | 2023-07-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
CN108699055B (zh) * | 2015-12-13 | 2020-10-23 | 杭州英创医药科技有限公司 | 用作抗癌药物的杂环化合物 |
US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
HUE055978T2 (hu) | 2016-08-15 | 2022-01-28 | Pfizer | Piridopirimidinon CDK2/4/6 inhibitorok |
JP6545747B2 (ja) * | 2017-05-09 | 2019-07-17 | 山田化学工業株式会社 | 色素化合物 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
EA036060B1 (ru) * | 2017-07-17 | 2020-09-21 | Пфайзер Инк. | Пиридопиримидиноновые ингибиторы cdk2/4/6 |
CR20200591A (es) | 2018-05-04 | 2021-03-31 | Incyte Corp | Sales de un inhibidor de fgfr |
WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
EP3797107B1 (en) * | 2018-05-21 | 2022-08-10 | Nerviano Medical Sciences S.r.l. | Heterocondensed pyridone compounds and their use as idh inhibitors |
WO2020006210A1 (en) * | 2018-06-27 | 2020-01-02 | Tufts Medical Center, Inc. | Pyridopyrimidine compounds and methods of their use |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
JP2022533182A (ja) * | 2019-05-16 | 2022-07-21 | ユニバーシティー オブ ヒューストン システム | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
MX2022004390A (es) | 2019-10-11 | 2022-08-08 | Incyte Corp | Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2). |
TW202128685A (zh) | 2019-10-14 | 2021-08-01 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
WO2021108803A1 (en) | 2019-11-26 | 2021-06-03 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as jak inhibitors |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
EP4118082A4 (en) * | 2020-03-13 | 2024-05-01 | Prosenestar LLC | PYRIDO[2,3-D PYRIMIDIN-7(8H)-ONE AS CDK INHIBITORS |
CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5733920A (en) * | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
FR2741881B1 (fr) * | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
US6498163B1 (en) * | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
ATE391719T1 (de) * | 1997-02-05 | 2008-04-15 | Warner Lambert Co | Pyrido (2,3-d) pyrimidine und 4-amino-primidine als inhibitoren der zellulären proliferation |
-
2000
- 2000-11-30 BR BR0017075-5A patent/BR0017075A/pt not_active IP Right Cessation
- 2000-11-30 AU AU18086/01A patent/AU1808601A/en not_active Abandoned
- 2000-11-30 CZ CZ20022521A patent/CZ20022521A3/cs unknown
- 2000-11-30 PL PL00357634A patent/PL357634A1/xx not_active Application Discontinuation
- 2000-11-30 IL IL15074200A patent/IL150742A0/xx unknown
- 2000-11-30 JP JP2001561007A patent/JP2003523358A/ja active Pending
- 2000-11-30 US US10/181,866 patent/US20040224958A1/en not_active Abandoned
- 2000-11-30 HU HU0203803A patent/HUP0203803A3/hu unknown
- 2000-11-30 SK SK1077-2002A patent/SK10772002A3/sk not_active Application Discontinuation
- 2000-11-30 WO PCT/US2000/032572 patent/WO2001055148A1/en not_active Application Discontinuation
- 2000-11-30 EP EP00980883A patent/EP1255755A1/en not_active Withdrawn
- 2000-11-30 CA CA002394525A patent/CA2394525A1/en not_active Abandoned
- 2000-11-30 KR KR1020027009631A patent/KR20020070520A/ko not_active Application Discontinuation
- 2000-11-30 CN CN00818672A patent/CN1433417A/zh active Pending
-
2001
- 2001-01-08 GT GT200100005A patent/GT200100005A/es unknown
- 2001-01-22 SV SV2001000287A patent/SV2002000287A/es not_active Application Discontinuation
- 2001-01-24 HN HN2001000012A patent/HN2001000012A/es unknown
- 2001-01-24 PA PA20018510801A patent/PA8510801A1/es unknown
- 2001-01-25 PE PE2001000082A patent/PE20011228A1/es not_active Application Discontinuation
- 2001-01-25 AR ARP010100308A patent/AR029437A1/es unknown
- 2001-01-25 CO CO01005602A patent/CO5280216A1/es not_active Application Discontinuation
- 2001-01-26 TN TNTNSN01018A patent/TNSN01018A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1255755A1 (en) | 2002-11-13 |
CO5280216A1 (es) | 2003-05-30 |
AR029437A1 (es) | 2003-06-25 |
CA2394525A1 (en) | 2001-08-02 |
JP2003523358A (ja) | 2003-08-05 |
US20040224958A1 (en) | 2004-11-11 |
HUP0203803A3 (en) | 2004-09-28 |
GT200100005A (es) | 2002-02-05 |
PL357634A1 (en) | 2004-07-26 |
IL150742A0 (en) | 2003-02-12 |
TNSN01018A1 (en) | 2005-11-10 |
AU1808601A (en) | 2001-08-07 |
PA8510801A1 (es) | 2002-12-11 |
WO2001055148A1 (en) | 2001-08-02 |
CN1433417A (zh) | 2003-07-30 |
PE20011228A1 (es) | 2002-01-18 |
CZ20022521A3 (cs) | 2003-02-12 |
KR20020070520A (ko) | 2002-09-09 |
BR0017075A (pt) | 2002-11-05 |
HUP0203803A2 (hu) | 2003-02-28 |
SK10772002A3 (sk) | 2004-01-08 |
SV2002000287A (es) | 2002-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HN2001000012A (es) | Tratamiento de la enfermedad neurodegenerativa | |
HN1997000052A (es) | Nuevas 4(3h)--quinazolinas 2,3-disustituidas | |
HN2002000208A (es) | 1-ALQUIL O 1 - CICLOALQUIL-TRIAZOLO [4.3 - a] QUINAZOLIN -5-ONAS COMO INHIBIDORES DE FOSFODIESTERASAS | |
ECSP024399A (es) | Derivados de benzotiazol | |
MEP42808A (en) | Use of flibanserin in the treatment of sexual disorders | |
HN1999000066A (es) | Formulaciones farmaceuticas | |
BR0114913A (pt) | Inibidores de metaloproteinase de espiro-pirimidina-2,4,6-triona | |
HN1998000115A (es) | Formas de dosificación farmacéuticas sólidas | |
EE200200716A (et) | Ühendid Alzheimeri tõve käitluseks | |
HN1999000015A (es) | Tratamiento para una disfuncion sexual femenina | |
MXPA02007915A (es) | Mediador de lipido activado por aspirina. | |
BR0307998A (pt) | Hidroxietilaminas substituìdas | |
BRPI0418031A (pt) | inibidores de quinase fosfonato-substituìdos | |
PA8513101A1 (es) | Derivados de eteres de pirazol como agentes anti- inflamatorios/analgesicos | |
PA8529701A1 (es) | Compuestos retinoides | |
HN2002000299A (es) | Derivados del 3- azabiciclo[3.1.0] hexano | |
DK1339407T3 (da) | Farnesylproteintransferaseinhibitorer til behandling af inflammatorisk tarmsygdom | |
PT1390371E (pt) | Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores | |
MY124786A (en) | Bis-arylsulfones | |
HN2002000110A (es) | Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple. | |
PA8514901A1 (es) | Metabolitos agonistas/antagonistas de estrogeno | |
AR021643A1 (es) | Combinacion de cerivastatina y fibratos. | |
SE9801494D0 (sv) | Novel use | |
CR7198A (es) | Tableta que contiene cetirizina y pseudoefedrina | |
ATE411279T1 (de) | Arylsulfonamidobenzylverbindungen |